Skip to content

The effectiveness of Vonoprazan for ulcer healing and prevention of delayed bleeding after gastric ESD: a prospective observational study.

The effectiveness of Vonoprazan for ulcer healing and prevention of delayed bleeding after gastric ESD: a prospective observational study. - The effectiveness of Vonoprazan for ulcer healing and prevention of delayed bleeding after gastric ESD.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000022269
Enrollment
250
Registered
2016-05-11
Start date
2016-11-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric tumor

Interventions

None listed

Sponsors

Kyoto Prefectural University of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Diagnosed gastric cancer as clinical T1a or gastric adenoma (2) Only one lesion will be performed by ESD. (3) Patients are accepted to enrollment and registration for this study. (4) Patients can be follow up for 56 days after ESD.

Exclusion criteria

Exclusion criteria: (1) Patients with active peptic ulcer (2) Patients with the history of gastrectomy (3) The lesion which are recurrence of endoscopic resection before (4) Patients with intake of mucosal protective agent or antacid (5) Patients with severe anemia (6) Patients with severe liver dysfunction (7) Patients with severe renal dysfunction (8) Patients with allergy for Vonoprazan (9) Patients without written informed consent (10) Patients with the possibility of the pregnancy or the pregnancy and lactating (11) Ineligible patients certified by doctors

Design outcomes

Primary

MeasureTime frame
To assess the rate of delayed bleeding after ESD by Vonoprazan at 6 weeks, compared with proton pomp inhibitor at 8 weeks.

Secondary

MeasureTime frame
To assess the rate of ulcer healing after ESD by Vonoprazan at 6 weeks, compared with proton pomp inhibitor at 8 weeks.

Countries

Japan

Contacts

Public ContactOsamu Dohi

Kyoto Prefectural University of Medicine Department of Gastroenterology and Hepatology

osamu-d@koto.kpu-m.ac.jp075-251-5519

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026